Senate Commission Says China Is Seizing Drug Supply Chain, Pushes For Congressional Action
A Senate commission warned that China is closing in on seizing control of the global drug and biopharma supply chains.
Libby Bandelin · Nov 19, 2026 · 4 min read

A Senate commission warned that China is closing in on seizing control of the global drug and biopharmaceutical supply chains.
The Senate National Security Commission on Emerging Biotechnology (NSCEB) released a new analysis on Thursday. It alleges that drug and biopharmaceutical companies making deals with Chinese biotech firms advance the Chinese Communist Party‘s (CCP) efforts to control the global pharmaceutical supply chain.
In an analysis of 57 deals made from the beginning of 2023 through October, the commission found that Western drugmakers are investing significant sums of money and signing licensing agreements with Chinese biotech firms.
These drugmakers include AstraZeneca, Bristol Myers Squibb and Pfizer who are taking advantage of China’s growing investment in biotechnology and the prospect of faster clinical trials and product approvals, Axios reported Thursday.
The Daily Caller News Foundation requested comment from media representatives at all three pharmaceutical companies but did not receive responses in time for publication.
“The CCP seeks dominance in biotechnology as a source of economic power and geopolitical advantage, and Beijing has spent decades pursuing a deliberate strategy to achieve that at all levels of the value chain,” NSCEB Executive Director Caitlin Frazer said in a Thursday press statement. “US-China pharma deals are starting to favor the Chinese startups, which risks eroding biotech R&D in the US. This trend should be alarming for policymakers.”
The announcement comes a day after the commission published a fact sheet for the bipartisan “National Biotechnology Safety Act,” which Republican Indiana Sen. Todd Young introduced in September 2025. The legislation was referred to the Committee on Health, Education, Labor and Pensions (HELP) during the 2025 session, which was last action Congress made toward advancing it.
Young, who also chairs the NSCEB, said in a statement to the DCNF that the latest findings underscore the growing threat China poses to dominated the global pharmaceutical market and the urgent need for Congress to act.
“We cannot afford to allow China to gain a competitive advantage in an industry so critical to our economic and national security,” Young said in a statement to the DCNF. “I remain committed to working with my colleagues to advance legislation, including the National Biotechnology Safety Act, to strengthen American leadership in biotechnology and protect our national security.”




